NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics Ltd (NASDAQ:ARCT) announced its earnings results on Monday, May, 13th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.15. The biotechnology company had revenue of $4.35 million for the quarter, compared to the consensus estimate of $3.47 million. Arcturus Therapeutics had a negative net margin of 63.05% and a negative return on equity of 160.16%. View Arcturus Therapeutics' Earnings History.

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics.

5 analysts have issued twelve-month target prices for Arcturus Therapeutics' shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Arcturus Therapeutics' share price to reach $18.00 in the next year. This suggests a possible upside of 67.6% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

News coverage about ARCT stock has trended somewhat positive on Sunday, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the next few days. View News Stories for Arcturus Therapeutics.

Arcturus Therapeutics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 88,400 shares, a decrease of 14.9% from the September 30th total of 103,900 shares. Based on an average trading volume of 78,800 shares, the short-interest ratio is presently 1.1 days. Approximately 1.3% of the company's shares are sold short. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include Basilea Pharmaceutica (BPMUF), ImmunoGen (IMGN), BioDelivery Sciences International (BDSI), Cytokinetics (CYTK), RAPT Therapeutics (RAPT), Retrophin (RTRX), AC Immune (ACIU), Kiniksa Pharmaceuticals (KNSA), Aprea Therapeutics (APRE), Intra-Cellular Therapies (ITCI), Provention Bio (PRVB), Kadmon (KDMN), Magenta Therapeutics (MGTA), Viking Therapeutics (VKTX) and Prothena (PRTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), KLA (KLAC), Terravia (TVIAQ), Corbus Pharmaceuticals (CRBP), Obsidian Energy (OBE), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO) and Arena Pharmaceuticals (ARNA).

Arcturus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dfpg Investments Inc. (3.23%), Sumitomo Mitsui Trust Holdings Inc. (2.09%), Nikko Asset Management Americas Inc. (2.09%), Sabby Management LLC (0.83%), Squarepoint Ops LLC (0.25%) and We Are One Seven LLC (0.10%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.

ARCT stock was purchased by a variety of institutional investors in the last quarter, including Dfpg Investments Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Sabby Management LLC, Squarepoint Ops LLC and We Are One Seven LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $10.74.

Arcturus Therapeutics has a market capitalization of $162.50 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]